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Abstract Since the first use of Chinese hamster ovary (CHO)
cells for recombinant protein expression, production process-
es have steadily improved through numerous advances. In this
review, we have highlighted several key milestones that have
contributed to the success of CHO cells from the beginning of
their use for monoclonal antibody (mAb) expression until to-
day. The main factors influencing the yield of a production
process are the time to accumulate a desired amount of bio-
mass, the process duration, and the specific productivity. By
comparing maximum cell densities and specific growth rates
of various expression systems, we have emphasized the lim-
iting parameters of different cellular systems and comprehen-
sively described scientific approaches and techniques to im-
prove host cell lines. Besides the quantitative evaluation of
current systems, the quality-determining properties of a host
cell line, namely post-translational modifications, were ana-
lyzed and compared to naturally occurring polyclonal immu-
noglobulin fractions from human plasma. In summary, numer-
ous different expression systems for mAbs are available and
also under scientific investigation. However, CHO cells are
the most frequently investigated cell lines and remain the
workhorse for mAb production until today.
Keywords Chinese hamster ovary (CHO) . Human
embryonic kidney (HEK) . NS0 . PER.C6 .Monoclonal
antibody (mAb) manufacturing .Mammalian expression
systems . Process advances . Optimization strategies
Historical and scientific background
Monoclonal antibodies are the largest group of recombinant
proteins used not only for human therapy but also for in vivo
imaging of different types of diseases.
In the mid-1970s, the foundation for the commercial suc-
cess of antibodies was laid by Köhler and Milstein who de-
veloped the method for immortalization of B lymphocytes for
the purpose of monoclonal antibody production (Köhler and
Milstein 1975). Isolated primary lymphocytes, differentiated
and matured in the body, are fused with immortal
lymphoblastoid cells, the so-called myeloma cells. Myeloma
cells had already been cultivated since the 1960s, and auxo-
trophic cell strains were established after intensive treatment
with chemicals or radiation. These early cell lines were then
used for scientific evaluation and were also needed for the
newly developed hybridoma technology enabling the discrim-
ination between fused and unfused cells. Despite similar at-
tempts at expressing other products with immortalized, differ-
entiated cells being undertaken, the upcoming pharma indus-
try in particular soon recognized the potential of mAbs as
future blockbusters. The reason was that hybridoma technol-
ogy was published in Nature in 1975 and therefore free of IP
rights (Köhler and Milstein 1975). Most importantly, individ-
ual antibodies are considered to be individual products and
can be patented to genera te market exclusiv i ty.
Consequently, the first protein from animal cell culture for
human application was OKT3, a mouse mAb directed against
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T lymphocytes to prevent host versus graft reaction in kidney
transplantation (Smith 1996).
The next generation of mAb-producing cell lines was driv-
en by the problems of hybridoma instability and the develop-
ment of human anti-mouse antibodies (HAMA) by the pa-
tients. Progress in molecular biology techniques and the fea-
sibility of directed genetic manipulation of mammalian cells
enabled the production of mAbs by recombinant cell lines
instead of less-defined hybridoma cells. The 1990s were dom-
inated by the development of chimeric antibodies with human
constant immunoglobulin regions and mouse variable regions
to prohibit HAMA responses in patients. To delete the remain-
ing T cell epitopes located on the variable regions of mAbs,
humanization strategies were developed by grafting the
antigen-binding domains (located on the complementary de-
termining regions and determined by three heavy chain and
three light chain peptide loops) to human framework regions
of existing antibodies or to the nearest related germline re-
gions. An alternative humanization strategy called resurfacing
is based on the identification of surface accessible residues to
evaluate their necessity for antigen binding or their potential
for generating a T cell epitope (Pedersen et al. 1994; Roguska
et al. 1994). However, the best method to generate a human
applicable mAb is still to start from original human genes.
Those might be obtained from antigen-primed donors as well
as naïve or immune libraries which are commercially avail-
able. In this case, IP rights need to be charged for the techno-
logical package.
The dominating production system for mAbs is a recombi-
nant expression in cellular systems. Not only the costs of the
final drug product is the most important decision-driving pa-
rameter for a production system but also downstream proce-
dures have to be evaluated carefully since they contribute
significantly to meeting all regulatory demands and clinical
efficacy. Product expense is a consequence of cost of goods
and available capacity of the production facility, which might
differ for the individual cell systems. A major impact is raised
by downstream procedures and product quality assurance
steps which cause significant costs even when cheap technol-
ogies with prokaryotic systems and lower eukaryotes are ap-
plied. In this review, the CHO production system is compared
to alternative systems by means of production capacity and
product quality.
Production systems under development, often already for
decades, are transgenic plants and animals as well as in vitro
translation systems. The difficulties which are encountered in
those systems are most often insufficient product titers (trans-
genic animals), unwanted glycosylation patterns or proteolytic
activity (both predominantly envisaged in transgenic plants),
rendering the downstream procedures complicated and ineffi-
cient. Besides the availability of these expression systems,
antibodies for human application are isolated by human plas-
ma fractionation as initially developed during World War II.
The industrial scale of single facilities is in the range of several
thousand liters run in shift operations (Robert and Hotchko
2013). Frozen or fresh plasma pools are fractionated to isolate
valuable components of the human serum proteome. One of
them is the immunoglobulin fraction which is sold as plasma-
derived intravenous immunoglobulin (IVIG), which is a poly-
valent product generated from 10,000 to 40,000 donors.
Plasma donations containing elevated levels of clinically im-
portant antibodies are preferably used for the production of
‘hyperimmune’ or ‘specific’ IgG products, such as anti-
hepatitis B, anti-tetanus, anti-cytomegalovirus, or anti-rabies.
To get an estimate of the production capacity, nearly 100 tons
of IVIG are used in clinical applications per year. This means
that the human individual also represents a factory for com-
mercial antibody production, and huge amounts are isolated
and purified from a worldwide cohort of millions of donors.
The factor Bproduction efficacy-yield^ in mAb production
Production yield is always a matter of numerous factors of the
complex procedure of mAb manufacturing and therefore
needs to be split into different unit operations to evaluate the
critical steps. One major step is the upstream process, starting
from the frozen vial of the producer clone and ending with the
harvest of the culture broth. Critical parameters in this proce-
dure are (i) the time until a desired cell density is reached,
determined by the specific growth rate (μ) of the cells; (ii)
the duration of the production phase enabling an accumulation
of recombinant protein from a high-density and viable culture;
and (iii) the obtainable product titer determined by the specific
production rate (qP) and the overall process duration.
Host cell lines for mAb production and host cell
engineering
The most prominent host cell lines for recombinant mAb ex-
pression are CHO, NS0, Sp2/0, HEK293, and PER.C6.
However, most literature is available for CHO cells, which
are still the workhorse for 70 % of today’s industrially pro-
duced protein therapeutics (Jayapal et al. 2007). In this con-
text, it should be noted that mAbs approved for human therapy
are only produced in CHO, NS0, and Sp2/0 (Dumont et al.
2015). Reviewed literature investigating high-producing cell
lines is often not available, sometimes for IPR reasons or
because only the process or the medium is of major interest
and the cell line serves only as a tool. Table 1 gives an over-
view of scientific publications without considering therapeutic
application.
CHO cells were used as an expression system for the first
approved recombinant biopharmaceutical (tissue plasminogen
activator; t-PA) in 1986. Since then, CHO cells have clearly
remained the preferred choice for recombinant protein expres-
sion. Despite other mammalian expression systems being
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available, CHO cells have clearly been at the center of atten-
tion for research on optimizing recombinant protein expres-
sion. Therefore, CHO-based mAb production processes have
matured considerably and typically reach the highest product
titers with ∼1 g/L in batch and 1–10 g/L in fed-batch processes
(Table 1).
The murine cell lines NS0 and Sp2/0 are also used for
recombinant mAb production despite expressing the two pre-
dominant immunogenic glycan epitopes for humans (Jefferis
2009), galactose-alpha1,3-Gal (alpha-gal), and N-glycolyl-
neuraminic acid (Neu5Gc). Both epitopes are absent in CHO
and baby hamster kidney (BHK) cells (both of hamster ori-
gin). In reported batch cultures, NS0 cells typically reached up
to tenfold lower cell andmAb concentrations than CHO-based
batch processes (Table 1). Despite achieving relatively high
specific productivities of 20–50 pg/cell/day, published mAb
titers range from 0.1 to 0.2 g/L in batch cultures and from 0.1
to 0.8 g/L in fed-batches.
Human embryonic kidney (HEK) and PER.C6 cells
are often discussed for human identical glycosylation.
However, especially for the production of mAbs, the
in vivo heterogeneity has to be considered since in dis-
tinct cases mAbs from CHO cells showed higher
sialylation compared to HEK cells (Croset et al. 2012).
HEK293 cells are especially applied for transient gene
expression to harvest a protein within a few days after
DNA delivery. At present, transiently transfected cells
reach mAb expression levels only in the low tens to
hundreds of milligrams per liter range during batch cul-
tivation. In fed-batches, mAb titers up to 0.6 g/L were
reported for a scFv-Fc antibody fragment (Jäger et al.
2013). Regarding PER.C6 cells, reported product yields
are more in the range of CHO-based processes with
mAb titers of 0.5 g/L (batch), 8 g/L (fed-batch), and
even 27 g/L (perfusion) as shown in Table 1.
Al though th i s i s impress ive , such h igh mAb
Table 1 Relevant bioprocess parameters for different mAb expression systems
Cell line Peak cell
concentration
Specific
growth rate
Specific
productivity
Yield STY Process type Reference
[106 cells/mL] [per day] [pg/cell/day] [g/L] [mg/(L × day)]
CHO 8.5 0.7 >50 0.9 121 Batch Reinhart et al. (2015)
23.9 0.7 >50 >5.8 345 Fed-batch Reinhart et al. (2015)
1.3 0.8 >2 0.04 2 Batch Lee et al. (2005)
27–33.5 n.a. >2 0.09–0.015 58–72 Perfusion Lee et al. (2005)
>10 0.7 57 >1 85 Fed-batch Zboray et al. (2015)
25; 26 n.a. 35; 49 10; 13 530; 730 Fed-batch Huang et al. (2010)
n.a. n.a. n.a. 9.8 470 Fed-batch Luan et al. (2006)
>200 n.a. 10–15 n.a. n.a. Perfusion Clincke et al. (2011)
<110 n.a. 9–13 n.a. n.a. Perfusion Clincke et al. (2013)
PER.C6 5 0.5 n.a. 0.3–0.5 42 Batch Jones et al. (2003)
>4 0.5 14–24 0.39 n.a. Batch De Kruif et al. (2010)
n.a. n.a. n.a. 8 n.a. Fed-batch Kuczewski et al. (2011)
≥150 n.a. n.a. 27a n.a. Perfusiona Kuczewski et al. (2011)
HEK 293b n.a. n.a. n.a. ≤0.3 43 Batch Hasegawa et al. (2014)
>2 n.a. 20 0.2 20 Batch Nallet et al. (2012)
2–4 n.a. 5–10 0.12–0.14c 24–28 Batch Jäger et al. (2013)
6–8 n.a. 5–10 0.1–0.6c <100 Fed-batch Jäger et al. (2013)
NS0 0.6–1.0 0.3–0.6 20–50 0.1–0.2 13–17 Batch Ho et al. (2012)
2.3 0.6–1.0 8–20 0.07 14 Batch Spens and Häggström (2007)
2.3–9.9 1.0 8–20 0.1–0.8 19–67 Fed-batch Spens and Häggström (2007)
2.4 0.5 1.9–13.4 0.24 17 Fed-batch Stansfield et al. (2007)
Values for the specific growth rate refer to the exponential growth phase
n.a. not available
a Product and cell retention in an extreme density bioreactor
b Transient mAb expression
c Product was a scFv-Fc antibody fragment
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concentrations at harvest were achieved due to product
retention and concentration during perfusion in the bio-
reactor (Kuczewski et al. 2011).
The process improvements, which are often only empir-
ically described, are escorted by achievements in vector de-
sign and genetic engineering of host cell lines. Vectors with
incorporated scaffold/matrix attachment regions (S/MAR)
(Zahn-Zabal et al. 2001; Kim et al. 2004; Girod et al.
2005) or ubiquitous chromatin opening elements (UCOEs)
(Benton et al. 2002) are designed to provide an Bactive^
configuration of chromatin loops surrounding the trans-
ferred gene of interest. Alternatively, bacterial artificial
chromosomes (BACs) are DNA transfer vectors carrying a
whole eukaryotic locus with all the elements controlling the
expression of a gene. Thus, the transgene on the BAC is
surrounded by an open/permissive chromatin loci and is
not affected by the chromatin environment of the integration
site (Kunert and Casanova 2013).
Host cell engineering aims to increase the duration of a
(fed-) batch process in the bioreactor. Apoptosis, the major
event of different cell death possibilities, is addressed in nu-
merous studies to develop apoptosis-resistant cell lines by
different strategies such as anti-apoptotic Bcl-2-like proteins
(García-Sáez 2012), the suppression of pro-apoptotic fac-
tors, or the inhibition of the p53 tumor suppressor protein
(Arden et al. 2007). Similarly, human telomerase reverse
transcriptase (hTert) was overexpressed in recombinant CHO
cells to induce the proliferation and promote apoptosis resis-
tance (Crea et al. 2006). While the above-mentioned points
aim to improve the growth and transcription potential of the
cell, other authors aimed to improve the translational capacity
of the cell by overexpression of chaperones for efficient mat-
uration of the recombinant and often complex proteins or to
reduce the unfolded protein response (UPR) to eliminate ap-
optosis events as a result of cellular stress (Davis et al. 2000;
Chung et al. 2004; Borth et al. 2005; Tigges and Fussenegger
2006; Mohan and Lee 2010). One additional limit of heterol-
ogous protein expression might be the secretion pathway,
starting from the translocation of the nascent polypeptide
chain into the endoplasmatic reticulum (ER). Improper signal
peptide cleavage from the antibody chain can lead to light
chain aggregation. To reduce this, Le Fourn et al. (2014)
overexpressed SRP14, a protein of the signal recognition par-
ticle (SRP), and thereby improved the specific productivity of
difficult-to-produce antibodies several-fold.
In addition to complete mAbs, also corresponding frag-
ments like scFv, scFvFc, Fab, and F(ab)2 are also used in
clinical applications and will be paid increasing attention
when the diversity of alternative diagnostic and therapeutic
drugs is boosted. Such mAb variants are often produced in
lower eukaryotes to circumvent technological difficulties and
the risk of contamination since high-cell densities are quickly
reached due to faster cell propagation. Among the different
yeast systems, Pichia pastoris is often preferred to
Saccharomyces cerevisiae for its ability to grow on different
carbon sources (including methanol), chemically defined me-
dia and the product secretion to the extracellular environment
(Macauley-Patrick et al. 2005). The ability of yeast cells to
perform post-translational modifications significantly reduces
the burden on downstream procedures compared to bacterial
systems. The resistance of P. pastoris to methanol and the
decreased fermentative metabolic pathway enable their cultiva-
tion to cell densities above 100 g/L dry cell mass in reusable
stainless steel systems (Cregg 2007; Gurramkonda et al. 2009).
Such high cell density cultures (HCDC) are often also cost-
intensive, and increased concentrations of extracellular prote-
ases might result from increased cell death (Cregg et al. 2000;
Shi et al. 2003; Daly and Hearn 2005). Due to the envisaged
limits in HCDC, the factor of improving specific protein pro-
duction rates is the main focus of improving recombinant pro-
tein production in yeast cells. Besides the commonly applied
codon optimization strategies, coexpression of helper factors
like HAC (bZIP transcription factor HAC-1 is involved in the
UPR) and SEC4 (involved in vesicular transport) or chaperones
actively supporting protein maturation in the ER have been
suggested and applied with different degrees of success
(Gasser et al. 2006; Damasceno et al. 2007). Therefore, the
specific growth rate, maximum cell densities as well as process
time shall be compared in a rough approximation in the follow-
ing section. Here, we want to compare the CHO system with
the methylotrophic yeast P. pastoris since both systems secrete
the recombinant product into the culture supernatant. Both ex-
pression systems are predominantly grown in synthetic chem-
ically defined media. Also, downstream procedures are compa-
rable even though increasingly high cell densities may consid-
erably challenge the cell separation step in the Pichia system.
For realistic comparison of the two systems, the most important
parameters describing the exponential growth phase up to the
stationary phase of a batch culture are summarized in Table 2.
The main and presumably the only advantage of P. pastoris
is its high specific growth rate. Considering this advantage,
Table 2 Growth parameters and maximum cell densities of a batch
process of P. pastoris and CHO cells.
Parameter Pichia pastoris CHO cells
Calculated cell massa [ng/cell] 0.02 2
Maximum cell concentration [cells/L] 1–2 × 1013 0.5–
1 × 1011
Maximum cell wet weight (WCW) [g/L] 200–400 100–200
Maximum specific growth rate [per h] 0.15 0.03
Values in italics are estimated (calculated) since they are usually not
quantified for the system. The specific gravity of cells is simplified with 1
a Cell mass is based on the assumption of spherical cells with a diameter
of 15–16 μm for CHO cells and 3–4 μm for P. pastoris cells
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Fig. 1 compares the accumulation of biomass using the
P. pastoris system in comparison with two theoretical CHO
growth curves, characterized by two different specific growth
rates (0.6 and 0.7/day); P. pastoris was calculated with
μ = 0.15/h. The wet cell weight (WCW) on the y-axis is
limited with 100 g/L indicating the estimated exponential
growth phase of the cultures.
This substantial difference in specific growth rate high-
lights the challenge of animal cell culture. This becomes even
more critical in a large-scale 20-kL bioreactor, which needs to
be filled to a maximum cell concentration of 5 × 1010 cells/L,
meaning 1015 cells have to be generated from a master cell
bank, which is normally frozen with 106 cells/vial. This re-
quires a process time of 29 days, and 2 tons of cells needs to be
generated.
A detailed study was conducted by Maccani et al. (2014),
who investigated recombinant clones of P. pastoris (host
strain SMD1168H) and CHO (host strain DUKX-B11) ex-
pressing two different model proteins. When a scFvFc homo-
dimeric mAb fragment (3D6scFvFc) was expressed, the max-
imum specific growth rate was 5–10 times higher in P.
pastoris. The mean specific secretion rate (qP expressed as
mg/g DCW/h) of 3D6scFvFc was more than 1000-fold higher
in the CHO cells compared to the P. pastoris strains. Due to
the low qP of the 3D6scFvFc in P. pastoris strains, the space
time yield (STY; mg/L/h) was almost tenfolds lower in P.
pastoris compared to the corresponding CHO cell line even
though the maximal cell dry mass concentration (g/L) of the P.
pastoris strain was more than 100-folds higher compared to
CHO strains.
Similar conclusions were made during a direct comparison
of CHO cells (DUKX-B11) with P. pastoris (wild-type strain
X33) which recombinantly expressed a heterodimeric Fab
fragment (Kunert et al. 2008). Similar to the 3D6scFvFc used
byMaccani et al. (2014), simple protein-free media based on a
DMEM:Ham’s F12 mixture supplemented with soy peptone
and other small-molecule protein-free supplements were used
for cell culture experiments.
Current and advanced technology of mAb production
Cell culture technology has matured considerably in the last
decades and evolved into a relatively reliable and robust tech-
nology. There are a number of steps to be optimized that
synergistically contribute to the successful exploitation of this
technology and produce a given recombinant protein at high
quantity and desired quality, while keeping the production
costs low.
One particular milestone was the development and com-
mercial availability of improved chemically defined media
that led to promising results even with rather old cell lines,
which were established long before the development of the
Bnew^ media. However, higher costs and individual demands
of each recombinant clone trigger the biopharmaceutical
companies to develop their own media to optimize their
mammalian cell technology platforms. Jayapal et al. (2007)
analyzed the development of cell culture technologies and
stated that almost 30 years ago, Bold^ bioprocesses were usu-
ally operated for a week in batch mode with peak cell concen-
trations of 3 × 106 cells/mL and recombinant protein yields of
approximately 100 mg/L (Fig. 2). Two decades later, state-of-
the-art processes reached considerably longer process dura-
tions, higher cell densities, and mAb titers of 1–5 g/L due to
improved basal media as well as feed strategies to replenish
depleted nutrients. Nowadays, further developments such as
specific feed concentrates that meet the different demands
during different cultivation phases (e.g., growth and stationary
phase) that enable even higher cell concentrations and product
titers beyond 10 g/L are becoming reality. Recently, continu-
ous process control strategies such as perfusion systems have
started to gain popularity due to a paradigm shift of cell culture
process development from pursuing even higher titers to
Fig. 1 Calculated exponential growth of P. pastoris and two CHO cell
lines. For P. pastoris, a startingWCWof 0.4 g/L (20 × 106 cells/mL) and a
μ of 0.15/h were assumed (full line), CHO cell lines were inoculated with
0.3 × 106 cells/mL (0.6 g/L) and a μ of 0.7/day (0.029/h) (dashed line),
and 0.6/day (0.025/h) (chain line) was estimated
Fig. 2 Typical cell and product concentrations achieved due to process
improvements in the past three decades
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controlling product quality and process consistency
(Kelley 2009). During perfusion, a constant supply of fresh
nutrients and removal of by-products can be achieved while
retaining the cells in the bioreactor. This creates a rather stable
environment for the product and the cells along with a short
retention time of the product to preserve its quality.
Additionally, such processes enable cell concentrations be-
yond 2 × 108 cells/mL (Clincke et al. 2013) and high produc-
tivities with mAb titers up to 27 g/L (Kuczewski et al. 2011)
due to product retention and concentration in the bioreactor.
Compared to batch or fed-batch processes, perfusion cultures
can reach several-fold higher space time yields (Table 1).
Another milestone in medium development was the move
towards serum-free media. Although serum promotes cell
growth, its non-standardized and complex composition is a
significant source of medium variability which lowers the out-
come and robustness of a bioprocess. As an alternative to
serum, animal-component free protein hydrolysates derived
from soy, wheat, and yeast can be added to support cell growth
and productivity. However, the composition of hydrolysates
also varies from lot to lot. Thus, to maximize process robust-
ness, the implementation of fully chemically defined media is
usually preferred.
Advances in monitoring and control strategies have gener-
ally improved process performance and robustness. Linking
the bioprocess to the cellular metabolism can be used to im-
plement cultivation strategies and fine-tune or direct, e.g., be-
tween cell growth and/or productivity as well as nutrient con-
sumption and by-product accumulation (Fan et al. 2014;
Reinhart et al. 2015). In general, by-product formation can
be reduced at low osmolality levels and therefore increase
culture viability, longevity, and recombinant protein produc-
tion. However, higher osmolalities have also been shown to
increase productivities (Zhang et al. 2010). Further strategies
to reduce unwanted by-products such as lactic acid (mainly
acidifies culture) or ammonium (toxic and negatively affects
protein glycosylation) are to keep glucose or glutamine concen-
trations low or directly substitute themwith slowlymetabolized
nutrients such as galactose or glutamate (Altamirano et al.
2001, 2004). Another rather simple strategy to reduce by-
product formation can be realized by reduction of the cell me-
tabolism by lowering temperature and/or pH (Trummer et al.
2006a, b).
Optimization of culture operating parameters is vitally im-
portant to obtain high product yields while meeting the quality
specifications. Physical (e.g., temperature, gas flow, and im-
peller speed), chemical (e.g., pH, osmolality, dissolved O2 and
CO2, redox potential, and metabolite levels), and biological
(e.g., cell concentration, viability, cell cycle, mitochondrial
activity, and NADH and LDH levels) parameters can all sig-
nificantly affect product quality and potency, especially with
respect to glycosylation, post-transcriptional modifications,
and impurity profiles (Li et al. 2010b). These factors can cause
substantial variability during bioprocessing. Little understand-
ing of the sources of variation in mammalian cell culture pro-
cesses is certainly one of the challenges ahead. Currently, a
better understanding of bioprocesses towards ensuring final
product quality is driven by the US Food and Drug
Administration’s (FDA) process analytical technology (PAT)
initiative and possibly links process parameters and reproduc-
ibility, culture performance, and product quality (FDA 2004).
Disposable technologies are continuously gaining more
importance and are nowadays no longer limited to laboratory
scale but are continuously being applied on a larger scale.
Compared to traditional stainless steel tanks, single-use biore-
actors offer numerous advantages such as lower initial invest-
ment costs, an increased reliability, and no validation efforts as
they arrive clean and pre-sterilized; minimal requirements for
installation, qualification, and personnel training and can in-
crease plant capacity and flexibility by reducing turnaround
and set-up time, with reduced piping, valve, and instrumenta-
tion requirements as well as faster implementation of design
changes allowing for continuous improvement and integration
of new technologies such as on-line monitoring systems
(Li et al. 2010b). Improved on-line and off-line sensors are
capable of providing information that further enhances pro-
cess monitoring and control. The first generation of on-line
probes for optical cell density quantification often showed
erroneous readings at decreasing viabilities at later stages of
bioprocesses. Next-generation probes rely on dielectric per-
mittivity and electrical impedance spectroscopy and are more
accurate to determine viable cell volume (Zeiser et al. 1999;
Downey et al. 2014). Spectroscopic probes, based on near- or
mid-infrared range, allow non-invasive assessment of com-
plex cell culture media components such as nutrients, by-
products, viability, and cell and recombinant product concen-
trations (Li et al. 2010a) directly in the bioreactor allow even
better process control in real time.
The factor Bproduct quality^ in mAb production
The primary sequence of a mAb expressed in different cell
systems is mainly determined by the codons of the transgene,
but post-translational modifications determine a recombinant
protein’s microheterogeneity and have a significant impact on
its solubility, stability, pharmacokinetics, potency, and biolog-
ical activities. Enzymatic modifications start with the cleavage
of the signal sequence and follow the path of protein matura-
tion in the ER and the Golgi. The aim of therapeutic protein
manufacturing is to generate proteins’ microheterogeneity as
close to the in vivo situation as possible. But especially for
polyclonal immunoglobulins from human serum, this is a very
complex picture despite the Fc fragment of all four IgG sub-
classes carrying only a single highly conserved N-
glycosylation site. The predominant structure of these
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oligosaccharides is a biantennary complex-type structure,
mostly core-fucosylated partially with a bisecting N-
acetylglucosamine, and a small portion may carry one or
two sialic acid residues on the antennae (Raju 2008). Themost
significant variation is determined by the degree of
galactosylation and a varying portion of truncated glycoforms.
Various studies have indicated that the glycosylation profile in
particular changes during age or specific physiological and
pathological conditions (Parekh et al. 1985; Yamada et al.
1997; Chen et al. 2012). Therefore, it is necessary to focus
on commonly described and discussed specific differences of
glycosylation like fucosylation, sialylation, occurrence of
bisecting N-acetylglucosamine, and the degree of
galactosylation.
Galactosylation is rather important for mediating
complement-dependent cytotoxicity (CDC), and different
studies confirmed the positive effect of fully galactosylated
IgG due to increased antibody binding to C1q (Jefferis
2009). In contrast, IgG half-life is not supported by terminal
galactose residues (Jones et al. 2007).
Alpha1,6-fucosylation is often discussed because of its role
in antibody-dependent cell-mediated cytotoxicity (ADCC)
initiated by binding of the specific antibody to the FcγRIIIa
receptor. Despite the fact that more than 80 % of serum IgG is
fucosylated, it has been found that non-fucosylated IgG’s in-
crease ADCC significantly (Miyoshi et al. 1999; Xue et al.
2013). Since CHO cell-expressed mAbs contain 90 %
fucosylated carbohydrates, host cells are genetically
engineered to lackα1,6-fucosyltransferase (Satoh et al. 2006).
The bisecting N-acetyl-glucosamine, bound to the central
mannose residue, is another important sugar moiety that is
known to improve ADCC. CHO and NS0 cells do not express
N-acetyl-glucosaminyl transferase III (Umaña et al. 1999),
and therefore, different groups aim to generate appropriate cell
lines (Ferrara et al. 2006).
Sialylationmight have a beneficial effect on serum half-life
(Raju and Lang 2014), but it has also been reported that ter-
minal sialic acid reduces ADCC (Scallon et al. 2007).
Beneath the highly inhomogeneous picture of glycosyla-
tion of mAbs and serum IgG, chemical or enzymatic
modifications of amino acids have been described. N-
terminal glutamic acid and glutamine might be converted to
pyroglutamate and C-terminal lysine can be cleaved off
(Brorson and Jia 2014). Cyclic pyroglutamate not only was
found in vivo but also occurs biologically after long
bioprocess duration and chemically during purification, for-
mulation, storage, or even under analytical procedures. After
lysine cleavage, the newly generated terminal proline residue
is now susceptible to another modification, namely amidation.
Plasma-derived antibodies generally lack C-terminal lysine
residues in their heavy chains (Harris 1995). Terminal modi-
fications were not estimated as having an impact on antigen or
receptor binding, but from a regulatory perspective, they
should be considered in risk-assessments and the impact on
product quality and safety should be studied.
Deamidation of asparagine and glutamine is sometimes
found in the antigen binding site of mAbs and was evaluated
to have a major impact on the binding affinity (Huang et al.
2005; Haberger et al. 2014). Other modifications like oxida-
tion of methionine (Liu et al. 2008), the formation of disulfide
bonds, or glycation (Quan et al. 2008) may also lead to mi-
croheterogeneity being defined as a critical quality attribute
and should be controlled carefully (Goetze et al. 2010).
The quality of mAbs needs to be controlled and assured for
the final product formulation until to the moment of in vivo
application. Biophysical properties, the heterogeneity in size,
and the net charge of the molecule are important parameters.
In-depth analysis of glycosylation variants are performed by
mass spectroscopy (MS). Due to the expensive equipment and
the demand of highly specialized scientists, it is assumed that
in the near future, MSwill be performed by designated protein
biochemists. However, since DoE protocols call for multi-
tudes of analyzed samples alternative techniques are adapted
to trace enzymatic and chemical changes to indicate the mAb
microheterogeneity. Such methods are often based on protein
size, surface charge, or the combination of both properties.
Protein aggregation and formation of particles commonly
occur during the bioprocess by structural, environmental, and
processing factors. The therapeutic protein can thereby lose
biological activity, develop immunologic reactions, or other
Fig. 3 Score of scientific
publications in PubMed (US
National Library of Medicine)
using diverse popular cell lines
for recombinant protein
expression in the last 10 years as
well as total results
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side effects. Therefore, analyzing product quality early in de-
velopment is necessary to rapidly match the desired quality
profile. A broad range of size (nm–μm) has to be considered
and complimentary, orthogonal analytical techniques are nec-
essary to verify the results based on different principles and
setups (Telikepalli et al. 2014). Size exclusion chromatogra-
phy (SEC) is a powerful tool to analyze smaller aggregates in
the size range of tens of nanometers but small nanometer-
sized soluble aggregates might dissociate by interacting with
the mobile phase or adhere to the column. Therefore, HIC-
HPLC was developed and gave promising results for the anal-
ysis of different mAb isoforms including aggregates
(Haverick et al. 2014). Alternatively, SEC was applied in an
HPLC format to improve isoform resolution (Paul et al. 2014).
Nanoparticle tracking analysis (NTA) is able to analyze sub-
micron particles (0.1 to 1 μm) by combining laser light scat-
tering microscopy with a charge-coupled device camera en-
abling the visualization and recording of nanoparticles in so-
lution. The complementary method is dynamic light scattering
(DLS) which determines particle size from fluctuations in
scattered light intensity due to the Brownian movement of
the particles, but accurate size determination is rather critical
with this method. Electron microscopy analysis provides
highly detailed information not only about particle size but
also about particle shape and surface texture. Currently, a
common application is limited since equipment is expensive
and analyses rely on microscope experts. The size distribution
determined by analytical ultracentrifugation (AUC) is also
more complex and needs to be combined with the above-
mentioned methods, such as PAGE and SEC including all
their uncertainties.
Analysis of charge variant distribution of mAb prepara-
tions gives insight to chemical and enzymatic modifications
of mAbs that may result from the bioprocess or the
formulation/storage conditions (Lingg et al. 2014).
Conventional ion-exchange chromatography needs to be elab-
orated for every single mAb, is a time-consuming procedure,
and needs several micrograms of mAb for each injection. This
led to the development of highly sensitive alternatives like
capillary ion-exchange chromatography (Rea et al. 2015)
and high-performance ion-exchange chromatography
(Kishishita et al. 2015) to analyze acidic, main, and basic
mAb fractions. To handle multiple samples in a short time
and evaluate different process strategies, Wheeler et al.
(2014) developed a microchip zone electrophoresis for high
throughput analysis of mAbs.
Conclusion
By summarizing biological and technological aspects for re-
combinant mAb production in different mammalian cell cul-
ture hosts, it becomes clear that despite their long scientific
history a lot of development work is still invested in them. The
number of scientific publications containing BCHO^ in the
title and text in PubMed (US National Library of Medicine)
far exceeds other commonly used cell lines for recombinant
protein expression (Fig. 3). Approximately 75 % of scientific
publications have used CHO cells since the beginning, and
this percentage has remained unchanged for the last 10 years.
Therefore, CHO cells will probably remain the workhorse for
protein expression in mammalian cell culture in the next de-
cades too. In parallel, much work was and will be put into the
development of alternative expression systems especially for
mAb variants without in vivo counterparts, new conjugated
formats, or artificial molecules. These may even be expressed
in lower eukaryotes or prokaryotes, depending on if they can
meet the desired quality specifications. Another point to con-
sider is the development of biosimilars where the community
has experienced difficulties in meeting the branded original
without precisely mimicking the whole production of the orig-
inal drug.
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